# Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy

> **NCT00135109** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 654 (actual)

## Conditions studied

- Diabetic Neuropathies

## Interventions

- **DRUG:** SPM 927

## Key facts

- **NCT ID:** NCT00135109
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 654 (ACTUAL)
- **Last updated:** 2014-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135109, "Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00135109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*